84 related articles for article (PubMed ID: 2272539)
1. Complement-mediated immune complex solubilization and precipitation inhibition in sera of patients with non-Hodgkin's lymphoma.
Bányai A; Pálóczi K; Csipö I; Csongor J; Szegedi G
Haematologia (Budap); 1990; 23(2):87-95. PubMed ID: 2272539
[TBL] [Abstract][Full Text] [Related]
2. Reaction of immune complexes with Hodgkin's disease tissue cultures: radioimmune assay and immunoferritin electron microscopy.
Long JC; Dvorak AM; Quay SC; Stamatos C; Chi SY
J Natl Cancer Inst; 1979 Apr; 62(4):787-97. PubMed ID: 372654
[TBL] [Abstract][Full Text] [Related]
3. Solubilization of immune complexes and inhibition of immune precipitation in SLE sera.
Balestrieri G; Pagani D; Tincani A
J Clin Lab Immunol; 1983 Nov; 12(3):147-50. PubMed ID: 6663608
[TBL] [Abstract][Full Text] [Related]
4. Reduced complement-mediated immune complex solubilization in leprosy patients.
Ramanathan VD; Sharma P; Ramu G; Sengupta U
Clin Exp Immunol; 1985 Jun; 60(3):553-8. PubMed ID: 3874729
[TBL] [Abstract][Full Text] [Related]
5. Formation of soluble immune complexes by complement in sera of patients with various hypocomplementemic states. Difference between inhibition of immune precipitation and solubilization.
Schifferli JA; Steiger G; Hauptmann G; Spaeth PJ; Sjöholm AG
J Clin Invest; 1985 Dec; 76(6):2127-33. PubMed ID: 2934406
[TBL] [Abstract][Full Text] [Related]
6. Complement-mediated solubilization of immune complexes in systemic lupus erythematosus.
Sakurai T; Fujita T; Kono I; Kabashima T; Yamane K; Tamura N; Kashiwagi H
Clin Exp Immunol; 1982 Apr; 48(1):37-42. PubMed ID: 6979449
[TBL] [Abstract][Full Text] [Related]
7. Circulating immune complexes, complement and complement component levels in childhood Hodgkin's disease.
Brandeis WE; Tan C; Wang Y; Good RA; Day NK
Clin Exp Immunol; 1980 Mar; 39(3):551-61. PubMed ID: 7379328
[TBL] [Abstract][Full Text] [Related]
8. Circulating immune complexes associated with decreased complement-mediated inhibition of immune precipitation in sera from patients with bacterial endocarditis.
Kerr MA; Wilton E; Naama JK; Whaley K
Clin Exp Immunol; 1986 Feb; 63(2):359-66. PubMed ID: 3698338
[TBL] [Abstract][Full Text] [Related]
9. Studies on the composition and elimination of circulating immune complexes in leukaemia.
Hollán SR; Füst G; Mód A; Puskás E; Nguyen Chi Phi
Haematologia (Budap); 1980; 13(1-4):263-82. PubMed ID: 7250813
[TBL] [Abstract][Full Text] [Related]
10. Changes of serum complement and of circulating immune complexes in patients with multiple sclerosis.
Cojocaru M; Serbănescu A; Cojocaru IM
Rom J Intern Med; 1993; 31(2):131-7. PubMed ID: 8268831
[TBL] [Abstract][Full Text] [Related]
11. Complement activation and impaired capacity to solubilize immune complexes or to prevent their formation in essential mixed cryoglobulinemia.
Corvetta A; Spaeth PJ; Ghirelli PA; Orecchioni F; Buetler R; Montroni M; Nydegger UE
Diagn Immunol; 1983; 1(4):315-23. PubMed ID: 6333960
[TBL] [Abstract][Full Text] [Related]
12. Solubilization of preformed immune complexes in sera of patients with type 1 and type 2 lepra reactions.
Chakrabarty AK; Kashyap A; Sehgal VN; Saha K
Int J Lepr Other Mycobact Dis; 1988 Dec; 56(4):559-65. PubMed ID: 3221112
[TBL] [Abstract][Full Text] [Related]
13. Study of the immune complex precipitation-inhibiting capacity of sera of patients with chronic lymphocytic leukaemia.
Varga L; Miszlay Z; Czink E; Pálóczi K; Szegedi G; Füst G; Hollán SR
Diagn Clin Immunol; 1987; 5(3):129-34. PubMed ID: 3319280
[TBL] [Abstract][Full Text] [Related]
14. Complement-mediated solubilization of immune complexes. Solubilization inhibition and complement factor levels in SLE patients.
Baatrup G; Petersen I; Kappelgaard E; Jepsen HH; Svehag SE
Clin Exp Immunol; 1984 Feb; 55(2):313-8. PubMed ID: 6230182
[TBL] [Abstract][Full Text] [Related]
15. Interaction of C3 with antigen-antibody complexes in the process of solubilization of immune precipitates.
Takata Y; Tamura N; Fujita T
J Immunol; 1984 May; 132(5):2531-7. PubMed ID: 6232320
[TBL] [Abstract][Full Text] [Related]
16. C4A deficiency and elevated level of immune complexes: the mechanism behind increased susceptibility to systemic lupus erythematosus.
Traustadottir KH; Sigfusson A; Steinsson K; Erlendsson K
J Rheumatol; 2002 Nov; 29(11):2359-66. PubMed ID: 12415592
[TBL] [Abstract][Full Text] [Related]
17. Detection of circulating immune complexes in patients with atopic dermatitis and psoriasis.
Kapp A; Kemper A; Schöpf E; Deicher H
Acta Derm Venereol; 1986; 66(2):121-6. PubMed ID: 2424234
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of complement-mediated solubilization of antigen-antibody complexes by sera from patients with rheumatoid arthritis.
Naama JK; Mitchell WS; Whaley K
Clin Exp Immunol; 1983 Nov; 54(2):429-38. PubMed ID: 6652966
[TBL] [Abstract][Full Text] [Related]
19. A comparative study of complement components in polyethylene glycol precipitated immune complexes from patients with ovarian cancer and patients with rheumatoid arthritis.
Mooney NA; Hay FC; Poulton TA
Clin Exp Immunol; 1983 Jun; 52(3):561-8. PubMed ID: 6603297
[TBL] [Abstract][Full Text] [Related]
20. Circulating immune complexes in Indian childhood cirrhosis.
Kalra V; Harkiss GD; Lachmann PJ; Ghai OP
Clin Exp Immunol; 1982 Oct; 50(1):1-6. PubMed ID: 6924609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
